Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

Contributed by: ACCESS Newswire

Logo

Tags

Healthcare & Pharmaceutical

Moderna, Inc.

NASDAQ:MRNA

Company Update

More Like This

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

National RSV vaccination programme announced